Palliativmedizin
Studienlage · Detail Kohortenstudie · Palliativmedizin · 2022

Survival rate of patients with combined hepatocellular cholangiocarcinoma receiving medical cannabis treatment: A retrospective, cohort comparative study.

Gemischt GRADE Niedrig 1 Zitate
Stichproben = 491 Pat.
DauerNachbeobachtung September 2019…
KontrolleStandard-Palliativschmerztherapie ohne…
EndpunktGesamtüberleben
Verblindungn.a.
DesignKohortenstudie
Kernaussage

Cannabis-Gruppe zeigte längere mediane Überlebenszeit (5,66 vs. 0,83 Monate) und niedrigere Mortalitätsrate, aber Autoren warnen vor unmeasured confounding und fordern prospektive Studien zur Bestätigung.

Zusammenfassung

Retrospektive Kohorte zu medizinischem Cannabis bei fortgeschrittenem cholangiozellulären Karzinom (CCA), n=491 (87 Cannabis-Therapie CT, 404 Standard-Palliativversorgung ST). Medianes Überleben CT=5.66 Monate (95% CI: 1.94–9.38) vs. ST=0.83 Monate (95% CI: 0.71–0.95). Multivariate Analyse: CT assoziiert mit verlängertem Überleben (HRadj=0.28; 95% CI: 0.20–0.37; p<0.001). Mortalitätsrate CT=10.9/100 Personenmonate vs. ST=48.35/100 Personenmonate. Autoren betonen mögliche Residual-Confounding.

P
PopulationErwachsene mit fortgeschrittenem Cholangiokarzinom (CCA), neu diagnostiziert, n=491 (ST: n=404, CT: n=87), Nordost-Thailand
I
InterventionMedizinisches Cannabis (palliative Behandlung, CT-Gruppe, n=87)
C
KontrolleStandard-Palliativschmerztherapie ohne Cannabis (ST-Gruppe, n=404)
O
OutcomeMedianes Überleben: 5,66 Monate (CT) vs. 0,83 Monate (ST); adjustierte HR=0,28 (95% CI: 0,20–0,37; p<0,001)
Vertrauen in die Evidenz
Niedrig

Zweite von vier GRADE-Stufen, die Effektschätzung ist begrenzt verlässlich.

Qualitätsprofil
Größe
Verblindung
Effektstärke Gemischt
Zitate / Jahr
Autoren
Phansila N, Pansila P, Wongkongdech A, Turnbull N, Azam M, Wongkongdech R
DOI 10.12688/f1000research.123250.3
Design: Kohortenstudie
Teilen
Abstract
Background: Cholangiocarcinoma (CCA) incidence in Northeastern Thailand is very high and a major cause of mortality. CCA patients typically have a poor prognosis and short-term survival rate due to late-stage diagnosis. Thailand is the first Southeast Asian country to approve medicinal cannabis treatment, especially for palliative care with advanced cancer patients. Methods: A retrospective cohort study compared survival among 491 newly diagnosed advanced CCA patients between September 2019 and June 2021. Of these, 404 received standard palliative pain management (ST), and 87 received medicinal cannabis treatment (CT). Patients were enrolled from four tertiary hospitals and two secondary hospitals in five provinces of Northeast Thailand. Cumulative survival was calculated by the Kaplan-Meier method, and independent prognostic factors were analyzed using Cox regression. Results: For ST patients, follow-up time was 790 person-months, with a mortality rate of 48.35/100 person-months. For CT patients, follow-up time was 476 person-months, with a mortality rate of 10.9/100 person-months. The median survival time after registration at a palliative clinic was 0.83 months (95% CI: 0.71-0.95) for ST and 5.66 months (95% CI: 1.94-9.38) for CT. Multivariate analysis showed CT was significantly associated with prolonged survival (HRadj = 0.28; 95% CI: 0.20-0.37; p < 0.001). Conclusions: The medical cannabis increased overall survival rates among CCA patients. In this retrospective cohort, Medicinal cannabis treatment was associated with more prolonged survival among advanced CCA patients in Northeastern Thailand. While this association remained significant after multivariable adjustment, unmeasured or residual confounding factors may have influenced the observed outcomes. Although the association remained significant after adjustment, unmeasured or residual confounders may have influenced outcomes. Further prospective studies are warranted to confirm these findings and explore potential mechanisms.

„Was dem Handeln im Weg steht, wird zum Weg.“ — Marc Aurel